Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopeifegestin for prevention of chemotherapy-induced neutropenia in non-small cell lung cancer
ChiCTR2000033931Phase 4Not yet recruiting
- Sponsor
- Huainan First People's Hospital
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in neutropenia, sponsored by Huainan First People's Hospital. Primary endpoint: Incidence of Grade 3-4 absolute neutrophil count reduction. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on ChiCTR2000033931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033931.